Peter Barschdorff (包培德)

The pharmaceutical industry is undergoing a significant transformation – an observation which is almost commonplace given the numerous changes and complex adjustments big pharma players are currently implementing, and have been implementing in recent years. - Clearly, all major pharmaceutical companies are refining their business models; making strategic acquisitions, shedding non-core assets, etc. – some with significant success, others without apparent reward. A form of Customer Value… Show more

The pharmaceutical industry is undergoing a significant transformation – an observation which is almost commonplace given the numerous changes and complex adjustments big pharma players are currently implementing, and have been implementing in recent years. - Clearly, all major pharmaceutical companies are refining their business models; making strategic acquisitions, shedding non-core assets, etc. – some with significant success, others without apparent reward. A form of Customer Value Creation is inherent in many of these initiatives. - However, responses from study participants suggest that there is a perception gap in many corners of this industry: between how executives view the market (and respond to it), and how the market evolves (and with what speed). Relationships with payers appear fairly strained, while physicians are looking to pharma for help. - Beyond case studies, we offer examples for Customer Value Integration in various customer segments, following the established “P-P-P” (physicians, payers, patients) model of commercial pharma. We detail lessons from Forward Integration in other industries and we propose the set of new competencies pharma has to develop and refine in order to meet today’s challenges. - Ultimately, Customer Value Integration will take different shapes and forms, depending on an individual company’s therapeutic area focus, product lifecycle stages and, of course, the nature of
the product. Show less

Delphi study of >38 U.S. experts on transatlantic relations, conducted at the critical period of realignment after key post-9/11 policy decisons. Insights included (1) U.S. relations with France and Germany had taken a serious hit in the aftermath of 9/11; (2) Counterterrorism will stay top-agenda for several years; (3) EU enlargement, while not without controversy, offers welcome opportunities for U.S. policy-making.

"Why are Europe and America still allied? After all, many observers predicted after the Cold War that NATO mght collapse, trade disputes could escalate, and political relations would suffer in the absence of a common threat (like the one formerly posed by the former Soviet Union). Peter Barschdorff argues that an acquis atlantique is holding the two sides together. Common experiences, legal stock and understadings make decision-makers convergee their views on controversial issues, such as… Show more

"Why are Europe and America still allied? After all, many observers predicted after the Cold War that NATO mght collapse, trade disputes could escalate, and political relations would suffer in the absence of a common threat (like the one formerly posed by the former Soviet Union). Peter Barschdorff argues that an acquis atlantique is holding the two sides together. Common experiences, legal stock and understadings make decision-makers convergee their views on controversial issues, such as peace-making in the Balkans, NATO reform and trade of agricultural goods. The acquis might change over time. But as an analytic concept and as a driver of transatlantic politics it will remain an important constant." Show less